Stock events for Omnicell, Inc. (OMCL)
Over the past six months, Omnicell's stock experienced several events. The company reported strong Q3 2025 results and acquired ANiGENT. Omnicell launched Omnicell Titan XT. Q4 2025 revenues increased, but EPS missed expectations, leading to a stock plunge. The stock price has seen fluctuations, and analyst sentiment is a "Moderate Buy" with an average 12-month target price of $54.50.
Demand Seasonality affecting Omnicell, Inc.’s stock price
Omnicell's demand exhibits some seasonality, with the first quarter typically including higher expenses, leading to sequential revenue declines. Overall demand is driven by the increasing awareness of automation benefits, demand for medication adherence packaging equipment, and the expanding North American healthcare automation market. The company has a significant backlog and serves approximately 80% of retail pharmacies in the United States.
Overview of Omnicell, Inc.’s business
Omnicell, Inc. is a healthcare technology company specializing in medication management solutions and adherence tools. The company focuses on pharmacy automation and medication management, aiming to improve patient safety, efficiency, and compliance. Its products include automated dispensing systems, central pharmacy automation, medication adherence solutions, and software and services like Performance Center and OmniSphere.
OMCL’s Geographic footprint
Omnicell's market presence is concentrated in the United States, accounting for 91% of its revenues in 2024. It also serves customers in Canada and has a global operational footprint, including a software development center in Bangalore, India, and offices in Australia, China, and France.
OMCL Corporate Image Assessment
Omnicell has maintained a positive brand reputation, being recognized as one of the Top 50 Healthcare Technology Companies in 2025. Randall Lipps was named one of the Top Healthcare Technology CEOs of 2025. The company operates in a regulated industry with inherent risks, and failure to comply could result in reputational damage.
Ownership
Omnicell's ownership is largely concentrated among institutional investors, who hold approximately 78.78% of the company's stock. Major institutional owners include BlackRock, Inc. and The Vanguard Group, Inc. Individual insiders, such as Randall A. Lipps, hold a smaller stake, with Lipps owning approximately 2.41% of the company's shares.
